Bharat Biotech's US partner says Covaxin is 65.2% effective against Delta variant

Efficacy data demonstrates 65.2% protection against the SARS-CoV-2, B.1.617.2 Delta variant.Efficacy analysis demonstrates Covaxin to be 93.4% protective against severe symptomatic COVID-19

from mint - Science https://ift.tt/2SJHC3P
https://ift.tt/eA8V8J